Cathepsin D (CatD) is also reported to involve in clearing Aβ and tau, and its inhibition by Aβ42 is observed in the early onset of AD and can be utilized as a potential biomarker (Chai et al., 2019; Suire et al., 2020). Here, MAPT is linked to Alzheimer disease.